Bouvel Investment Partners LLC Acquires 9,458 Shares of CRISPR Therapeutics AG $CRSP

Key Points

• Bouvel Investment Partners LLC increased its stake in CRISPR Therapeutics AG by 43.6%, acquiring an additional 9,458 shares during the second quarter, bringing their total holdings to 31,161 shares valued at $1,516,000.
• CRISPR Therapeutics reported earnings of ($1.29) per share for the most recent quarter, surpassing estimates, while revenues were $0.89 million, significantly below analysts' expectations of $6.44 million.
• Institutional investors own approximately 69.20% of CRISPR Therapeutics' stock, with several hedge funds such as ARK Investment Management and Green Alpha Advisors also increasing their positions in the company.

Bouvel Investment Partners LLC raised its position in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 43.6% during the second quarter, according to its most recent filing with the SEC. The firm owned 31,161 shares of the company's stock after purchasing an additional 9,458 shares during the period. Bouvel Investment Partners LLC's holdings in CRISPR Therapeutics were worth $1,516,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently added to or reduced their stakes in the business. ARK Investment Management LLC lifted its stake in CRISPR Therapeutics by 13.3% in the first quarter. ARK Investment Management LLC now owns 10,165,400 shares of the company's stock valued at $345,929,000 after buying an additional 1,192,336 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in CRISPR Therapeutics by 182.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,952,751 shares of the company's stock valued at $66,452,000 after buying an additional 1,262,560 shares during the period. Vanguard Group Inc. lifted its stake in CRISPR Therapeutics by 1.9% in the first quarter. Vanguard Group Inc. now owns 1,769,709 shares of the company's stock valued at $60,223,000 after buying an additional 33,711 shares during the period. Orbis Allan Gray Ltd lifted its stake in CRISPR Therapeutics by 5.9% in the first quarter. Orbis Allan Gray Ltd now owns 1,562,932 shares of the company's stock valued at $53,187,000 after buying an additional 86,813 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in CRISPR Therapeutics by 2.1% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 690,191 shares of the company's stock valued at $27,166,000 after buying an additional 13,865 shares during the period. 69.20% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have issued reports on CRSP shares. Bank of America dropped their price target on CRISPR Therapeutics from $79.00 to $78.00 and set a "buy" rating on the stock in a research note on Tuesday, July 22nd. HC Wainwright reaffirmed a "buy" rating and set a $80.00 target price on shares of CRISPR Therapeutics in a research report on Tuesday. Chardan Capital reaffirmed a "buy" rating and set a $82.00 target price on shares of CRISPR Therapeutics in a research report on Tuesday, August 5th. Royal Bank Of Canada upped their target price on CRISPR Therapeutics from $38.00 to $42.00 and gave the stock a "sector perform" rating in a research report on Tuesday, August 5th. Finally, Barclays upped their target price on CRISPR Therapeutics from $42.00 to $56.00 and gave the stock an "equal weight" rating in a research report on Wednesday, August 6th. Ten equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $71.50.

CRISPR Therapeutics Trading Down 1.4%

CRISPR Therapeutics stock traded down $0.89 during trading on Tuesday, hitting $61.21. 1,577,754 shares of the company were exchanged, compared to its average volume of 2,557,434. The business's 50 day moving average is $57.27 and its 200 day moving average is $46.46. CRISPR Therapeutics AG has a 52 week low of $30.04 and a 52 week high of $71.13. The company has a market capitalization of $5.57 billion, a P/E ratio of -11.27 and a beta of 1.81.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last announced its quarterly earnings data on Monday, August 4th. The company reported ($1.29) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.47) by $0.18. The firm had revenue of $0.89 million during the quarter, compared to the consensus estimate of $6.44 million. CRISPR Therapeutics had a negative return on equity of 20.05% and a negative net margin of 1,229.43%.The business's revenue for the quarter was up 72.5% on a year-over-year basis. During the same quarter in the prior year, the company earned ($1.49) EPS. Equities analysts expect that CRISPR Therapeutics AG will post -5.16 EPS for the current year.

Insider Transactions at CRISPR Therapeutics

In other CRISPR Therapeutics news, Director Simeon George acquired 989,812 shares of CRISPR Therapeutics stock in a transaction on Wednesday, July 16th. The stock was purchased at an average price of $52.03 per share, for a total transaction of $51,499,918.36. Following the purchase, the director directly owned 1,730,179 shares of the company's stock, valued at $90,021,213.37. This trade represents a 133.69% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 4.10% of the stock is owned by company insiders.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.